header logo image header logo text
Downloads Login
Research
General Information
ZIRC
ZFIN ID: ZDB-FISH-150901-5796
Fish name: um14Tg
Genotype: um14Tg
Targeting Reagent: none
HUMAN DISEASE MODELED by um14Tg
No data available
GENE EXPRESSION
Gene expression in um14Tg
Protein expression
Antibody Antigen Genes Structure Conditions Figures
Ab1-abcb11 standard conditions Fig. 2 with image from Dimri et al., 2017
Fig. 1Fig. 2Fig. 6 from Ellis et al., 2017
Fig. 3Fig. 6 from So et al., 2017
Fig. 3 with image from Ningappa et al., 2015
Ab5-pak control Fig. 3 with image from Dimri et al., 2017
Ab1-abcb11 chemical treatment by environment: XAV939 Fig. 2 with image from Dimri et al., 2017
Fig. 6 from Ellis et al., 2017
Fig. 6 from So et al., 2017
Ab3-prox1 standard conditions Fig. 1 with image from Zhang et al., 2017
Fig. 3 with image from Ningappa et al., 2015
Ab-2F11 control Fig. 1 from So et al., 2017
Ab1-prkcz control Fig. 5 with image from Dimri et al., 2017
Ab5-pak chemical treatment by environment: OLOMOUCINE Fig. 3 with image from Dimri et al., 2017
Ab10-casp3 chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
Ab10-GFP standard conditions Fig. 3 with image from Ningappa et al., 2015
Ab2-nkx6 standard conditions Fig. 6 with image from Ghaye et al., 2015
Ab2-tp63 standard conditions Fig. 8 with image from Fischer et al., 2014
Ab1-prkcz chemical treatment by environment: OLOMOUCINE Fig. 5 with image from Dimri et al., 2017
Ab2-dlc standard conditions Fig. 5 with image from Quillien et al., 2014
Ab10-casp3 standard conditions Fig. 8 with image from Fischer et al., 2014
Ab-2F11 chemical treatment by environment: XAV939 Fig. 1 from So et al., 2017
Ab1-cldn15lb cldn15lb standard conditions Fig. 3 with imageFig. 4 with image from Cheung et al., 2012
Ab1-etv2 etv2 standard conditions Fig. 5 with image from Quillien et al., 2014
Ab1-s100 s100b standard conditions Fig. 2 from Chapouton et al., 2010
PHENOTYPE
Phenotype in um14Tg
Phenotype Conditions Figures
bile canaliculus decreased length, abnormal chemical treatment by environment: XAV939 Fig. 1Fig. 6 from So et al., 2017
bile canaliculus decreased length, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 with image from Ningappa et al., 2015
bile canaliculus length, normal chemical treatment by environment: OLOMOUCINE Fig. 2 with image from Dimri et al., 2017
bile ductule branchiness, abnormal chemical treatment by environment: OLOMOUCINE Fig. 2 with image from Dimri et al., 2017
bile ductule decreased branchiness, abnormal chemical treatment by environment: OLOMOUCINE Fig. 4 with image from Dimri et al., 2017
bile ductule decreased branchiness, abnormal chemical treatment by environment: cucurbitacin E Fig. 4 with image from Dimri et al., 2017
bile ductule increased branchiness, abnormal chemical treatment by environment: IPA-3 Fig. 4 with image from Dimri et al., 2017
bile ductule increased branchiness, abnormal chemical treatment by environment: LimKi 3 Fig. 4 with imageFig. 6 with image from Dimri et al., 2017
bile ductule actin filament disconnected, abnormal chemical treatment by environment: XAV939 Fig. 1 from So et al., 2017
bile ductule cholangiocyte Ab5-pak labeling increased amount, abnormal control Fig. 3 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium decreased occurrence, abnormal chemical treatment by environment: cucurbitacin E Fig. 4 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium decreased occurrence, abnormal chemical treatment by environment: OLOMOUCINE Fig. 4 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium increased occurrence, abnormal chemical treatment by environment: IPA-3 Fig. 4 with image from Dimri et al., 2017
bile ductule morphogenesis of a branching epithelium increased occurrence, abnormal chemical treatment by environment: LimKi 3 Fig. 4 with imageFig. 6 with image from Dimri et al., 2017
caudal division of the internal carotid artery EGFP expression decreased amount, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: cucurbitacin E Fig. 5 with image from Dimri et al., 2017
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: LimKi 3 Fig. 5 with image from Dimri et al., 2017
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: IPA-3 Fig. 5 with image from Dimri et al., 2017
cholangiocyte actin cytoskeleton organization process quality, abnormal chemical treatment by environment: OLOMOUCINE Fig. 5 with image from Dimri et al., 2017
cholangiocyte filopodium decreased length, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 with image from Ningappa et al., 2015
cholangiocyte morphogenesis of a polarized epithelium process quality, normal chemical treatment by environment: LimKi 3 Fig. 5 with image from Dimri et al., 2017
cholangiocyte morphogenesis of a polarized epithelium process quality, normal chemical treatment by environment: OLOMOUCINE Fig. 5 with image from Dimri et al., 2017
cranial vasculature artery EGFP expression absent, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
dorsal aorta EGFP expression absent, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: 17beta-estradiol Fig. 4 with image from Carroll et al., 2014
dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: genistein Fig. 5 with image from Carroll et al., 2014
dorsal aorta EGFP expression decreased amount, abnormal chemical treatment by environment: 17alpha-ethynylestradiol Fig. 5 with image from Carroll et al., 2014
intrahepatic bile duct development disrupted, abnormal chemical treatment: tyrphostin AG 1478 Fig. 4 with image from Ningappa et al., 2015
jaw flap has fewer parts of type breeding tubercle, abnormal chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
jaw flap has fewer parts of type breeding tubercle, abnormal chemical treatment: pharmaceutical Fig. 8 with image from Fischer et al., 2014
jaw flap breeding tubercle decreased size, abnormal chemical treatment: pharmaceutical Fig. 8 with image from Fischer et al., 2014
jaw flap breeding tubercle decreased size, abnormal chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
keratinocyte proliferation disrupted, abnormal chemical treatment: DAPT Fig. 8 with image from Fischer et al., 2014
liver has extra parts of type cholangiocyte, abnormal chemical treatment by environment: IPA-3 Fig. 4 with image from Dimri et al., 2017
liver has extra parts of type cholangiocyte, abnormal chemical treatment by environment: LimKi 3 Fig. 4 with image from Dimri et al., 2017
liver has normal numbers of parts of type cholangiocyte, normal chemical treatment by environment: OLOMOUCINE Fig. 2 with imageFig. 4 with image from Dimri et al., 2017
liver has normal numbers of parts of type cholangiocyte, normal chemical treatment by environment: cucurbitacin E Fig. 4 with image from Dimri et al., 2017
liver volume, normal chemical treatment by environment: OLOMOUCINE Fig. 2 with image from Dimri et al., 2017
liver intrahepatic bile duct development decreased process quality, abnormal chemical treatment by environment: OLOMOUCINE Fig. 2 with image from Dimri et al., 2017
optic artery EGFP expression absent, abnormal chemical treatment: LY-411575 Fig. 2 from Rochon et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic multipotent progenitor cell, abnormal chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic multipotent progenitor cell, abnormal chemical treatment by environment: Cyclopamine Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic stem cell, abnormal chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta has fewer parts of type hematopoietic stem cell, abnormal chemical treatment by environment: Cyclopamine Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta lacks parts or has fewer parts of type hematopoietic stem cell, abnormal chemical treatment by environment: Cyclopamine, chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015
ventral wall of dorsal aorta lacks parts or has fewer parts of type hematopoietic multipotent progenitor cell, abnormal chemical treatment by environment: Cyclopamine, chemical treatment by environment: calciol Fig. 2 with image from Cortes et al., 2015

CITATIONS  (55)